Oseltamivir: Neuraminidase Inhibitor for Influenza Treatment and Prophylaxis

Oseltamivir (brand name Tamiflu) is an orally administered antiviral drug belonging to the neuraminidase inhibitor class. It is a prodrug, converted in the liver to its active form, oseltamivir carboxylate, which inhibits the neuraminidase enzyme expressed on the surface of influenza A and B viruses. Neuraminidase is essential for the release of newly formed viral particles from infected cells and for the spread of the virus within the respiratory tract; by blocking this enzyme, oseltamivir interrupts the influenza viral replication cycle.

Oseltamivir has been a central component of pandemic preparedness stockpiling strategies globally, given its oral route of administration and established activity against both influenza A and B, including pandemic strains. Its clinical utility is time-dependent: antiviral treatment must be initiated within 48 hours of symptom onset to achieve meaningful clinical benefit in most otherwise healthy adults. In high-risk populations, including elderly patients, immunocompromised individuals, and those with severe underlying medical conditions, the benefit window may extend slightly and the clinical impact of treatment is potentially greater due to the higher risk of severe influenza complications in these groups.

Mechanism of Action

Influenza viruses express neuraminidase (also called sialidase) glycoprotein spikes on their surface. Neuraminidase cleaves sialic acid residues from the surface of infected host cells and from the surface of newly budding viral particles, a process essential for the efficient release of progeny virions from infected cells and for preventing viral self-aggregation. Without functional neuraminidase, newly assembled influenza virions remain attached to the surface of infected cells, clumping together rather than dispersing to infect new cells, and are more efficiently eliminated by mucosal defenses such as mucus and ciliary clearance. Oseltamivir carboxylate, the active metabolite, is a competitive inhibitor of neuraminidase that binds tightly to the enzyme's active site, mimicking the transition state of the natural sialic acid substrate. Binding prevents neuraminidase from cleaving sialic acid, thereby trapping viral particles at the cell surface. The result is a reduction in the spread of infection within the respiratory tract, a shorter duration of viral replication, and an attenuation of the intensity of the inflammatory response and associated symptoms. Oseltamivir carboxylate inhibits neuraminidase from influenza A (including H1N1, H3N2, and avian strains such as H5N1) and influenza B subtypes, though activity against influenza B is generally somewhat lower. Oseltamivir resistance through neuraminidase mutations (most notably H275Y in N1 neuraminidase) has been documented and is monitored by global influenza surveillance networks.

Indications

Oseltamivir is approved for two distinct clinical uses. For treatment, it is indicated for influenza A and B infection in adults and children (including neonates) who have been symptomatic for no more than 48 hours. The 48-hour window is important because viral replication peaks early in the illness course; antiviral benefit decreases substantially when treatment is delayed beyond this point. In hospitalized patients with severe influenza or in high-risk individuals (elderly, immunocompromised, chronic cardiorespiratory disease, pregnancy, morbid obesity), treatment may still be considered beyond 48 hours as benefit has been observed in some high-risk settings even with later initiation. For prophylaxis, oseltamivir is indicated for the prevention of influenza following exposure to a confirmed or probable case. Post-exposure prophylaxis is particularly relevant for household contacts of influenza cases, healthcare workers with confirmed exposure, and immunocompromised patients. Seasonal prophylaxis throughout the influenza season is approved for adults in some countries, primarily for individuals at high risk who cannot be vaccinated or whose vaccine response is inadequate. Annual influenza vaccination remains the primary prevention strategy and is complementary to rather than replaced by antiviral prophylaxis.

Dosage and Administration

For treatment in adults and adolescents 13 years and older, oseltamivir is dosed at 75 mg twice daily for 5 days. For prophylaxis in adults and adolescents, 75 mg once daily is given for at least 10 days after a close exposure contact. For children, dosing is weight-based: children 1 to 12 years receive 30, 45, or 60 mg twice daily for treatment depending on weight (below 15 kg, 15 to 23 kg, and 23 to 40 kg respectively), with 75 mg twice daily for those over 40 kg; prophylaxis doses are half the treatment dose given once daily. Neonates (under 1 year) may receive 3 mg per kilogram twice daily for treatment, though this age group requires specialist guidance. Oseltamivir is available as hard capsules (30, 45, and 75 mg) and as an oral suspension (6 mg/mL), the latter being particularly useful in pediatric dosing and for patients who cannot swallow capsules. In patients with renal impairment (eGFR below 30 mL/min), dose reduction is required: 30 mg twice daily for treatment and 30 mg once daily for prophylaxis are recommended for severe renal impairment. Oseltamivir should be taken with food to reduce gastrointestinal side effects.

Side Effects

Gastrointestinal side effects are the most frequently reported adverse effects of oseltamivir. Nausea and vomiting occur in approximately 10 to 20 percent of patients and are the primary reason for treatment discontinuation in clinical practice. Taking oseltamivir with food substantially reduces nausea in most patients. Abdominal pain, diarrhea, and headache are also commonly reported. These effects are generally mild to moderate, transient, and rarely severe enough to require cessation of therapy in the context of treating influenza, where the disease itself causes significant symptoms. Neuropsychiatric adverse events, including self-injury, hallucinations, confusion, and abnormal behavior, received significant attention following reports from Japan, where the drug's widespread use in children coincided with reports of psychiatric events and, in some cases, fatal self-harm. However, causality has been difficult to establish because influenza itself, particularly in children, can cause neuropsychiatric manifestations including delirium. Regulatory agencies, including EMA and FDA, added warnings and have requested post-marketing surveillance. The current consensus is that influenza-associated neuropsychiatric complications cannot be fully distinguished from drug-related events based on available data. Patients and caregivers should monitor for unusual behavior during treatment. Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely.

Interactions

Oseltamivir has a limited pharmacokinetic drug interaction profile, which is clinically advantageous given that influenza patients often have multiple comorbidities requiring concurrent medications. Probenecid, an inhibitor of renal tubular secretion of organic anions, significantly increases exposure to oseltamivir carboxylate by reducing its renal elimination; this interaction can approximately double oseltamivir carboxylate AUC. While not typically a clinical concern in treatment courses, it should be considered in patients already taking probenecid (used for gout). Live attenuated intranasal influenza vaccine (LAIV) efficacy may be reduced if administered within two weeks before or two days after oseltamivir, as the antiviral activity can interfere with viral replication needed for LAIV immunogenicity; inactivated influenza vaccine is not affected. Oseltamivir does not have significant interactions with antibiotics, analgesics, antihypertensives, or most other commonly co-prescribed medications. It is not meaningfully metabolized by CYP450 enzymes, relying instead on hydrolysis by hepatic esterases, which reduces the likelihood of pharmacokinetic interactions.

Special Notes

Oseltamivir is not a substitute for influenza vaccination. Annual vaccination against influenza remains the most effective preventive measure for at-risk individuals and the general population. Antiviral treatment with oseltamivir is most beneficial in high-risk patients and those with severe influenza; healthy adults with uncomplicated influenza typically experience only modest shortening of symptom duration (by approximately one day on average based on meta-analyses). The Cochrane review by Jefferson et al., which analyzed unpublished clinical trial data, raised questions about the extent of oseltamivir's clinical benefit and the adequacy of evidence for reduction of serious complications such as pneumonia. Current clinical guidelines from organizations such as the WHO, CDC, and ECDC generally recommend oseltamivir treatment for hospitalized patients with confirmed or suspected influenza, for high-risk outpatients with severe illness, and for post-exposure prophylaxis in high-risk individuals. Global surveillance for oseltamivir-resistant influenza strains is maintained by the WHO global influenza surveillance network.

Related Topics

• Zanamivir
• Baloxavir

Frequently Asked Questions

Sources

• Jefferson T et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014.
• WHO: WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. 2010.
• EMA: Tamiflu (oseltamivir) Summary of Product Characteristics, current version.